Compare Heron Therapeutics Inc (HRTX) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Ralph Lauren Corp — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Ralph Lauren Corp trades at $382.47 (market cap $22.41B). The key difference: Ralph Lauren Corp is far larger — about 245× Heron Therapeutics Inc's market cap, and Ralph Lauren Corp pays a 0.99% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | RL | |
|---|---|---|
Market Cap | $91.46M | $22.41B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $414.25 |
52-Week Low | $0.39 | $283.34 |
Enterprise Value | $189.36M | $23.35B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Ralph Lauren (RL) trades at $376.55, down 1.03% on the day, with a neutral technical signal and key support at $370. The company demonstrates strong fundamentals, with revenue growing to $7.08B in 2025 and net income of $742.9M, supported by a 69.87% gross margin and consistent earnings beats. Analyst consensus is bullish with a $445.71 price target, and recent news highlights brand strength and digital expansion.
The outlook for RL is positive, driven by earnings momentum and strategic initiatives, though premium valuation and market volatility present risks. Upside potential exists if the company maintains its growth trajectory and meets Q2 2026 EPS expectations of $4.26.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
